Table 1.
Baseline characteristics between CAS and non-CAS.
Fig 1.
Spline smoothing plot between novel inflammation markers and carotid atherosclerosis.
A non- linear relationship between novel inflammation markers and carotid atherosclerosis after adjusting for age, gender, body mass index, aspartate aminotransferase, triglyceride, total cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol, estimated glomerular filtration rate, uric acid, hypertension, diabetes, osteoporosis, fatty liver, smoking history, drinking history. CAS, carotid atherosclerosis; PLR, platelet to lymphocyte ratio; NLR, neutrophil to lymphocyte ratio; LMR, lymphocyte to monocyte ratio; PNR, platelet to neutrophil ratio; NLPR, neutrophil to lymphocyte platelet ratio; SII, systemic immune-inflammation index; SIRI, systemic inflammation response index; AISI, aggregate index of systemic inflammation.
Fig 2.
The ORs and 95% CI of novel inflammatory indicators to CAS risk by logistic regression.
Model 1 adjusted for none. Model 2 adjusted for age, sex, and body mass index. Model 3 adjusted for age, gender, body mass index, aspartate aminotransferase, triglyceride, total cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol, estimated glomerular filtration rate, uric acid, hypertension, diabetes, osteoporosis, smoking history, drinking history. Forest plot of novel inflammatory markers for carotid atherosclerosis risk after adjusting for Model 3. PLR, platelet to lymphocyte ratio; NLR, neutrophil to lymphocyte ratio; LMR, lymphocyte to monocyte ratio; PNR, platelet to neutrophil ratio; NLPR, neutrophil to lymphocyte platelet ratio; SII, systemic immune-inflammation index; SIRI, systemic inflammation response index; AISI, aggregate index of systemic inflammation.
Fig 3.
Receiver operating characteristic (ROC) curves of all inflammatory markers for identifying carotid atherosclerosis risk.
PLR, platelet to lymphocyte ratio; NLR, neutrophil to lymphocyte ratio; LMR, lymphocyte to monocyte ratio; PNR, platelet to neutrophil ratio; NLPR, neutrophil to lymphocyte platelet ratio; SII, systemic immune-inflammation index; SIRI, systemic inflammation response index; AISI, aggregate index of systemic inflammation.
Table 2.
Evaluation of the predictive effect of the novel inflammatory markers on risk of CAS by ROC curves.
Table 3.
Association between NLPR and CAS in subgroups.